{"id":1419858,"title":"Résumé du RIEM : Inhibiteurs du SGLT2 et risque d’amputation transtibiale - IRSC","sourceCode":"cihr","sourceName":"Canadian Institutes of Health Research","language":"fr","captureDate":"2026-05-02","captureTimestamp":"2026-05-02T18:38:16.928000+00:00","jobId":8,"originalUrl":"https://cihr-irsc.gc.ca/f/53777.html","snippet":"Résumé du RIEM Inhibiteurs du SGLT2 et risque d’amputation transtibiale Étude menée par le Réseau canadien pour l’étude observationnelle des médicaments ( CNODES) Quelle est la question? Les inhibiteurs du cotransporteur sodium glucose de type 2 (SGLT2) sont une nouvelle classe…","rawSnapshotUrl":"/api/snapshots/raw/1419858","browseUrl":"https://replay.healtharchive.ca/job-8/20260502183816/https://cihr-irsc.gc.ca/f/53777.html#ha_snapshot=1419858","mimeType":"text/html","statusCode":200,"captureBackend":"browsertrix","captureFidelity":"high"}